-
Je něco špatně v tomto záznamu ?
Current Advances in Allosteric Modulation of Muscarinic Receptors
J. Jakubik, EE. El-Fakahany
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
19-05318S
Grantová Agentura České Republiky - International
RVO:67985823
Akademie věd České Republiky - International
NLK
Directory of Open Access Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
PubMed
32085536
DOI
10.3390/biom10020325
Knihovny.cz E-zdroje
- MeSH
- agonisté muskarinových receptorů metabolismus MeSH
- alosterická regulace fyziologie MeSH
- antagonisté muskarinových receptorů metabolismus MeSH
- lidé MeSH
- ligandy MeSH
- receptory muskarinové metabolismus fyziologie MeSH
- receptory spřažené s G-proteiny MeSH
- vazebná místa MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Allosteric modulators are ligands that bind to a site on the receptor that is spatially separated from the orthosteric binding site for the endogenous neurotransmitter. Allosteric modulators modulate the binding affinity, potency, and efficacy of orthosteric ligands. Muscarinic acetylcholine receptors are prototypical allosterically-modulated G-protein-coupled receptors. They are a potential therapeutic target for the treatment of psychiatric, neurologic, and internal diseases like schizophrenia, Alzheimer's disease, Huntington disease, type 2 diabetes, or chronic pulmonary obstruction. Here, we reviewed the progress made during the last decade in our understanding of their mechanisms of binding, allosteric modulation, and in vivo actions in order to understand the translational impact of studying this important class of pharmacological agents. We overviewed newly developed allosteric modulators of muscarinic receptors as well as new spin-off ideas like bitopic ligands combining allosteric and orthosteric moieties and photo-switchable ligands based on bitopic agents.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012855
- 003
- CZ-PrNML
- 005
- 20210507101641.0
- 007
- ta
- 008
- 210420s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biom10020325 $2 doi
- 035 __
- $a (PubMed)32085536
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Jakubik, Jan $u Department of Neurochemistry, Institute of Physiology CAS, 142 20 Prague, Czech Republic
- 245 10
- $a Current Advances in Allosteric Modulation of Muscarinic Receptors / $c J. Jakubik, EE. El-Fakahany
- 520 9_
- $a Allosteric modulators are ligands that bind to a site on the receptor that is spatially separated from the orthosteric binding site for the endogenous neurotransmitter. Allosteric modulators modulate the binding affinity, potency, and efficacy of orthosteric ligands. Muscarinic acetylcholine receptors are prototypical allosterically-modulated G-protein-coupled receptors. They are a potential therapeutic target for the treatment of psychiatric, neurologic, and internal diseases like schizophrenia, Alzheimer's disease, Huntington disease, type 2 diabetes, or chronic pulmonary obstruction. Here, we reviewed the progress made during the last decade in our understanding of their mechanisms of binding, allosteric modulation, and in vivo actions in order to understand the translational impact of studying this important class of pharmacological agents. We overviewed newly developed allosteric modulators of muscarinic receptors as well as new spin-off ideas like bitopic ligands combining allosteric and orthosteric moieties and photo-switchable ligands based on bitopic agents.
- 650 _2
- $a alosterická regulace $x fyziologie $7 D000494
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a vazebná místa $7 D001665
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a agonisté muskarinových receptorů $x metabolismus $7 D018721
- 650 _2
- $a antagonisté muskarinových receptorů $x metabolismus $7 D018727
- 650 _2
- $a receptory spřažené s G-proteiny $7 D043562
- 650 _2
- $a receptory muskarinové $x metabolismus $x fyziologie $7 D011976
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a El-Fakahany, Esam E $u Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA
- 773 0_
- $w MED00188737 $t Biomolecules $x 2218-273X $g Roč. 10, č. 2 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32085536 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507101641 $b ABA008
- 999 __
- $a ok $b bmc $g 1651099 $s 1133234
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 10 $c 2 $e 20200218 $i 2218-273X $m Biomolecules $n Biomolecules $x MED00188737
- GRA __
- $a 19-05318S $p Grantová Agentura České Republiky $2 International
- GRA __
- $a RVO:67985823 $p Akademie věd České Republiky $2 International
- LZP __
- $a Pubmed-20210420